Vigabatrin does not affect the intestinal absorption of phenytoin in rat duodeno-jejunal loops in situ.
The antiepileptic drug vigabatrin (GVG) is known to decrease significantly the serum concentration of concurrently administered phenytoin (PHT) in epileptic patients. To assess a possible mechanism for this interaction, the effect of GVG on the intestinal absorption of PHT was investigated by means of circulation experiments in an in situ rat duodeno-jejunal loop. GVG did not affect the rate of disappearance of PHT from the loop perfusing medium, providing evidence against occurrence of GVG-induced impairment of PHT absorption.
Tonini
M
M
Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Gatti
G
G
Manzo
L
L
Olibet
G
G
Coccini
T
T
Perucca
E
E
D000614:Aminocaproates / Q000494:pharmacology*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D004386:Duodenum / Q000378:metabolism; D007408:Intestinal Absorption / Q000187:drug effects*; D007583:Jejunum / Q000378:metabolism; D008297:Male; D010672:Phenytoin / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D010672:Phenytoin; D020888:Vigabatrin